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Mast cells are located at host interfaces, such as the skin, and contribute to the
first-line defense against pathogens by releasing soluble mediators, including those
that induce itching and scratching behavior. Here, we show that delta-hemolysin (Hld)
and phenol soluble modulins (PSMs) PSMα1 and PSMα3, but not alpha-hemolysin
(Hla) or Panton-Valentine leukocidin (PVL), induce dose-dependent tryptase, and lactate
dehydrogenase (LDH) release by the HMC-1 human mast cell line. Using supernatants
from isogenic strains, we verified that tryptase and LDH release was Hld- and
PSMα-dependent. PSMα1 and Hld production was detected in 65 and 17% of human
Staphylococcus aureus-infected skin abscess specimens, respectively, but they were
produced in vitro by all clinical isolates. The results suggest that Hld and PSM-α1
produced in vivo during S. aureus skin infections induce the release of mast cell
mediators responsible for itching and scratching behavior, which may enhance skin
to skin transmission of S. aureus via the hands. As Hld and PSMs are upregulated
by accessory gene regulator (agr), their association may contribute to the elective
transmission of S. aureus strains with a functional agr system.
Keywords: Staphylococcus aureus, mast cells, phenol-soluble modulins, delta hemolysin, virulence, accessory
gene regulator, hand-transmission
INTRODUCTION
Microorganisms are increasingly being recognized to have profound effects on the host they invade
(Shropshire and Bordenstein, 2016). In many cases, host behaviors are altered upon infection by
diverse pathogens, including bacteria (Cameron and Sperandio, 2015). These observed changes in
host behavior are often thought to be beneficial to the microorganisms, as they may increase the
rate of transmission (Cézilly and Perrot-Minnot, 2005).
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Staphylococcus aureus is both a commensal and extremely
versatile pathogen and one of the most common causes of
bacterial community and healthcare-associated infections in
humans (Lowy, 1998). S. aureus primarily causes skin and
soft tissue infections (SSTIs), bloodstream infections, and
pneumonia. The pathogenicity of S. aureus is determined by the
extended repertoire of toxins produced by this bacteria (Kong
et al., 2016). In vitro and in vivo studies in animals have identified
pore-forming toxins, such as Panton-Valentine leukocidin (PVL),
alpha-hemolysin (Hla), phenol-soluble modulin-alpha (PSMα),
and delta-hemolysin (Hld), as major virulence factors involved
in the pathophysiology of staphylococcal skin infections (Wang
et al., 2007; Kobayashi et al., 2011; Lipinska et al., 2011;
Syed et al., 2015). These toxins are capable of targeting a
wide variety of immune cells during infection, such as human
polymorphonuclear leukocytes, monocytes, and macrophages,
and can significantly contribute to dampening both innate and
adaptive immune response to S. aureus infection (Pozzi et al.,
2015).
The expression of PVL, Hla, and PSMs is regulated in different
manners by accessory gene regulator (agr), a quorum sensing
system in S. aureus. Hld is encoded by RNAIII, a non-coding
RNA that orchestrates the expression of most virulence factors
(Novick et al., 1993), including PVL and Hla (Vandenesch et al.,
1991; Dumitrescu et al., 2011). In contrast, PSMα expression is
regulated by AgrA, the response regulator of the two component
system that activates the agr system (Lina et al., 1998; Queck et al.,
2008).
Skin to skin contact via the hands plays a significant role in the
spread of S. aureus to new hosts not only in hospitals, but also in
nursing homes and child care settings, among others (Bloomfield
and Scott, 1997). Increasing the frequency of contact between
one’s hand and skin colonized or infected by S. aureus due to
itching and scratching behavior may enhance the transmission
potential of the pathogen. The induction of scratching behavior
in animals during experimental skin infection by S. aureus
was described a long time ago (Wagner et al., 1997) but only
recently described in humans when skin infections induced
by community-acquired methicillin-resistant S. aureus (CA-
MRSA) were misidentified by both patients and physicians as
spider bites because they were very erythematous, indurated,
and itchy, sometimes with a central dermo-necrosis (Suchard,
2011).
The skin is considered a major interface of the body for the
host defense, not only as a passive barrier, but also through
the immune system. Innate immune cells residing in the skin,
such as Langerhans cells, dendritic cells, and dermal mast
cells, provide cutaneous immune surveillance (Kupper and
Fuhlbrigge, 2014). Mast cells are leukocytes originating from
hematopoietic progenitor cells and located at host interfaces with
the environment, such as the skin, pulmonary, and digestive
mucosa. Mast cell differentiation and maturation are different
according to the organs in which they are located. Two major
phenotypes of mature mast cells are differentiated by granule
content and the receptors expressed: Phenotype T contains
mainly tryptase, and phenotype TC contains mainly tryptase and
chymase (Galli et al., 2011).
These cells are able to recognize pathogenic agents and
trigger the inflammatory process through complex inter-cellular
communication mediated by several mediators released by mast
cells. Thus, mast cells participate in the first line of defense in
innate immunity against pathogens, including bacteria (Abraham
and St. John, 2010).
Mast cells express several receptors capable of recognizing
pathogens that belong to pattern recognition receptor (PRR)
family involved in the recognition of pathogen-associated
molecular patterns (PAMPs), such as Toll-like receptors (TLRs)
TLR1 to TLR9, Nod-like receptors (NLRs), and C-type lectin
receptors (CLRs), including dectin-1 (Urb and Sheppard, 2012;
St. John and Abraham, 2013). Pathogen recognition induces
several activation pathways in mast cells, resulting in the release
of mediators, such as intra-cytoplasmic granules (histamine,
protease, tryptase, tumor necrosis factor [TNF]), lipid-derived
eicosanoids (leukotrienes and prostaglandins), and cytokines or
chemokines, including TNF, IL-4, and IL-6 (Abraham and St.
John, 2010; Urb and Sheppard, 2012; St. John and Abraham,
2013). After bacterial invasion, mast cells preferentially release
IL-8 and TNF to promote polymorphonuclear neutrophil (PMN)
recruitment at the infection site (Urb and Sheppard, 2012). First,
TNF, IL-6, and IL-8 promote PMN chemotaxis. Next, TNF and
eicosanoid trigger an up-regulation of adhesion molecules on the
endothelial cell surface and vascular permeability, allowing PMN
adhesion to endothelial cells and diapedesis (Abraham and St.
John, 2010). In addition, mast cells can directly kill pathogens via
the production of antimicrobial peptides known as cathelicidins
(Di Nardo et al., 2003).
Mast cells can recognize bacteria through TLR-2 and TLR-
4, which recognize the lipopolysaccharides of Gram-negative
bacteria and peptidoglycans of Gram-positive bacteria, and
through TLR-5, which recognizes flagellin (Abraham and St.
John, 2010). Mast cell mediators are also known to activate
neuroreceptors on sensory nerve fibers involved in the induction
of pruritus (Ständer et al., 2008).
Only a few studies have examined the interaction between
S. aureus and mast cells. S. aureus induces mast cell activation
through peptidoglycan-sensing by TLR2 (Feng et al., 2007). Two
recent studies also confirmed that S. aureus-exposed mast cells
release pro-inflammatory cytokines, such as IL-8, IL-3, IL-13, and
TNF-α (Rönnberg et al., 2014; Swindle et al., 2015). Furthermore,
S. aureus internalization by mast cells is enhanced by Hla
and induces the release of extracellular traps, antimicrobial
compounds, and pro-inflammatory cytokines (Abel et al., 2011;
Goldmann et al., 2016; Johnzon et al., 2016). Nakamura et al.
(2013) also demonstrated in a mouse model that S. aureus Hld
induces skin mast cell activation, promoting the establishment of
atopic dermatitis, an allergic skin disease. However, no data are
yet available on the effect of other staphylococcal toxins involved
in skin pathophysiology on human mast cells.
The aim of our study was to investigate whether S. aureus
produces virulence factors during skin infection that may
increase the rate of transmission by stimulating itching and
scratching behavior through mast cell activation. We examined
the impact of virulence factors involved in skin infection
pathophysiology on skin mast cell activation and verified
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there in vivo production in human S. aureus skin abscess
samples.
MATERIALS AND METHODS
Staphylococcal Virulence Factors and
Cells
The staphylococcal virulence factors used in this study were PVL,
Hla, Hld, PSMα1, and PSMα3. The recombinant proteins LukS-
PVL, LukF-PVL, and Hla were produced in our laboratory and
resuspended in phosphate buffered saline (PBS) as described
previously (Perret et al., 2012). Recombinant PVL activity on
the plasma membranes of human polymorphonuclear leukocytes
(PMNs) was verified on human PMNs before the study
(Supplementary Figure 1). Briefly, purified LukS-PV and LukF-
PV were diluted in RPMI to equimolar concentrations (0.05–
0.5 µg/mL, i.e., 0.0015–0.015µM) and mixed with human PMNs
(106 cells) in the presence of 500 ng propidium iodide (PI).
The percentage of PI-positive PMNs was determined by flow
cytometry (Becton Dickinson Accuri C6 Flow Cytometer) at 5,
10, 15, 20, 25, and 30 min.
The activities of alpha-hemolysin preparations were also
confirmed by cell permeability assays using rabbit erythrocytes
(Supplementary Figure 2). Recombinant Hla was diluted in
PBS (0.001–10 µg/mL, i.e., 3 × 10−5–0.3 µM) and mixed at
equal volume in a solution of 2% washed rabbit erythrocytes
(bioMérieux). After 60 min of incubation at 37◦C, samples were
centrifuged at 200 × g for 5 min and the OD405nm of the
supernatantsmeasured. The percentage hemolysis of each sample
was compared to that of erythrocytes lysed with 1% Triton-X.
PSMα1, PSMα3, and Hld were synthesized in the N-
formylated form by Genecust Europe R© (Luxembourg) with a
purity greater than 90% and resuspended in PBS before their
use. The HMC-1 human mast cell line was kindly provided by
Olivier Lortholary (Pasteur Institute, Paris, France) and cultured
in Iscove’s modified Eagle’s medium (IMDM) supplemented with
10% fetal calf serum (FCS) and 40 µg/mL gentamicin in 5% CO2
at 37◦C. For cell experiments, HMC-1 cell cultures were adjusted
to 1× 106 cells/mL in IMDM without FCS.
S. aureus Strains and Bacterial Culture
Twenty-three S. aureus clinical strains isolated from SSTIs were
provided by the French National Reference Center (NRC) for
Staphylococci. For each strain, the agr group, MLST-clonal
complex or sequence type (ST), mecA, Luk-PV gene, Hla, and
Hld were detected using a S. aureus microarray genotyping kit
(Alere, Jouy-en-Josas, France) as described previously (Monecke
et al., 2009) (Table 1). Moreover, isogenic mutants of a S.
aureus USA300-0114 clinical strain, SF8300, were constructed
using the oligonucleotides in Supplemental Table S1 and the
pKOR1 allelic replacement mutagenesis system as described
previously (Bae and Schneewind, 2006; Diep et al., 2010).
SF83001psmα1–4 and SF83001agrA mutants contain in-frame
deletions of genes encoding PSM-alpha types α1-α4 and AgrA.
SF8300Hld(3G > T) mutant contains a single nucleotide change
that changes the start codon ATG to ATT to block the initiation
TABLE 1 | Epidemiological characteristics of S. aureus strains isolated
from SSTIs.
S. aureus isolate Strain characteristics
agr MLST or mecA luk-PV
group Clonal Complex detection detection
ST 2012 0567 1 152 − +
ST 2014 0236 1 398 − −
ST 2011 1376 1 398 − −
ST 2013 0774 1 398 − −
ST 2008 1085 1 188 − +
ST 2012 1286 1 188 − +
ST 2013 1093 1 22 − +
ST 2007 1243 3 30 − +
ST 2014 0589 1 8 − −
ST 2014 1539 1 45 − −
ST 2013 1442 1 97 − −
ST 2012 0823 1 22 − −
ST 2012 1497 1 152 − +
ST 2014 0351 1 97 − −
ST 2007 1031 3 80 + +
ST 2011 1384 2 5 + −
ST 2015 1708 1 398 − −
ST 2012 0341 3 80 + +
ST 2007 0901 3 30 − +
ST 2010 1173 1 8 + +
ST 2010 2118 3 80 + +
0150331644 3 30 − −
ST 2011 0395 2 5 − −
ST 2013 1215 1 45 − −
ST 2014 1054 1 45 − −
ST 2015 1706 1 25 − −
ST 2012 0150 1 45 − −
ST 2009 1153 2 5 − −
ST 2014 1173 3 80 + +
ST 2012 1322 3 80 − +
ST 2014 0441 3 30 − −
HT 2004 1093 3 88 − +
ST 2010 1734 2 15 − −
ST 2014 1524 2 2482 − +
ST 2015 1705 3 30 − −
ST 2013 1745 1 8 − −
ST 2014 1033 2 5 + −
ST 2014 0409 3 30 − +
ST 2013 1301 2 15 − −
ST 2015 1710 3 30 − −
ST 2011 0514 3 30 − −
ST 2009 0867 1 8 − −
ST 2015 1711 3 30 − −
ST 2015 1707 2 5 − −
ST 2014 1501 3 30 − −
ST 2015 1709 2 5 − −
Underlined isolates correspond to clinical samples analyzed for toxin quantification.
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of its translation. Colonies of SF8300WT, SF83001psmα1–4,
and SF8300Hld(3G > T) were hemolytic on blood agar plate
suggesting that agr was functional in these mutants. AgrA-
knockout induces an alteration of the agr system and PSMα1–
4 production (Peschel and Otto, 2013). S. aureus supernatants
were prepared by growing bacteria adjusted to 0.5 MacFarland
standard in 3 mL of CCY broth in a rotary shaker (190 rpm)
at 37◦C for 22 h, followed by centrifugation for 10 min at 3000
× g to obtain a pellet. Supernatants were stored at −80◦C until
needed.
Clinical Samples
The study was conducted in accordance with the guidelines
of the ethical committees of the participating hospital, Centre
Hospitalier Lyon Sud (Hospices civils de Lyon, Pierre Bénite,
France) or Groupement Hospitalier Est (Hospices civils de
Lyon, Bron, France) (DC-201-1306). Specimens from human
S. aureus skin abscesses were collected as part of the routine
management of patients and stored at−80◦C in Eppendorf tubes.
A total of 23 samples were obtained and analyzed. For one
patient, two samples were collected. For the 23 S. aureus isolates,
characterization by microarray (Table 1) and culture supernatant
collection were carried out as described above.
Mast Cell Activation/Degranulation and
Lysis Assay
HMC-1 cells (1 × 106 cells/mL) were incubated in Eppendorf
tubes with PVL (0.05, 0.5, or 5 µg/mL, i.e., 0.0015, 0.015, 0.15
µM respectively), Hla (10 µg/mL, i.e., 0.3 µM), PSMα1, PSMα3,
Hld (0.1, 0.5, 1, 5, 10, 25, 50, 100, or 200 µg/mL, i.e., around 0.04,
0.2, 0.4, 2, 4, 9, 20, 40, or 80 µM respectively), SF8300 wild-type
(WT), SF83001psmα1–3, SF8300Hld(3G> T), or SF83001agrA
supernatants (20, 10, 5, or 1% v/v) for 3 h at 37◦C. Toxin
concentrations were inferred from previous studies on human
PMNs (Löﬄer et al., 2010) and preliminary results (data not
published). The cells were pelleted by centrifugation at 200 × g
for 10 min and the supernatants collected to measure tryptase by
Immunocap (Phadia R©) assay and lactate dehydrogenase (LDH
by Architect c16000 (Abbott R©) assay. Mast cell degranulation
and lysis were evaluated through tryptase release and LDH
release, respectively, and expressed as percentages using the
following formula: % = Tryptase Test−Tryptase TnegTryptase Tpos−Tryptase Tneg × 100. The
negative control (Tneg) was obtained using untriggered cell
buffer and the positive control (Tpos) using cell lysis solution
(Promega R©).
PVL and Hla Quantification in Bacterial
Supernatants
The PVL level in the supernatant was quantified using a specific
ELISA kindly provided by bioMérieux (R&DDepartment, Marcy
l’Étoile, France) as described elsewhere (Badiou et al., 2008).
The concentration of Hla in the supernatant was quantified
using a specific sandwich-type ELISA kindly provided by
GlaxoSmithKline Vaccines that targets Hla with a solid-phase
GlaxoSmithKline (GSK) monoclonal antibody, anti-Hla. The
antibody–antigen complex was detected by a GSK polyclonal
rabbit anti-Hla antibody followed by a peroxidase-conjugated
goat anti-rabbit antibody as described previously (Otto et al.,
2013).
PSM Quantification in Bacterial
Supernatants and Clinical Specimens
Bacterial supernatants were thawed at 4◦C, diluted 1:5 with
methanol at 4◦C, and incubated for 10 min at 4◦C. After
centrifugation at 10,000 × g for 5 min, the supernatants
were recovered for PSM quantification. Clinical specimens were
thawed to 4◦C, vortexed for 1 min, sterilized by 1 h of heating
at 94◦C, cooled on ice to 4◦C, diluted 1:5 with methanol at
4◦C, and incubated for 10 min at 4◦C. After centrifugation at
10,000 × g for 5 min, the supernatants were recovered for PSM
quantification. PSMα1, PSMα3, and Hld were quantified by high-
performance liquid chromatography mass spectrometry (HPLC-
MS) in an Agilent R© system using an adaptation of a method
described elsewhere (Wang et al., 2007).
Statistical Analysis
T-tests, ANOVA, Kruskal-Wallis tests following by Bonferroni-
adjusted Wilcox tests or t-tests, and a Pearson correlation test
were performed to compare mast cell degranulation andmast cell
lysis, as well as PSM andHld production. P≤ 0.05 was considered
significant.
RESULTS
The Effect of Toxins on HMC-1 Cells
Because in vitro and in vivo studies in animals have been
implicated PSMα1, PSMα3, Hld, Hla, and PVL in the
pathophysiology of skin infections, we examined their effect on
HMC-1 cells by measuring the tryptase and LDH release. The
range of concentrations used for each toxin was inferred from the
literature (Badiou et al., 2008; Löﬄer et al., 2010). We observed
that PSMα1, PSMα3, and Hld induced tryptase and LDH release
from HMC-1 cells in a dose-dependent manner (Kruskal-Wallis
tests, p < 0.001 for PSMα1, PSMα3, and Hld; Figures 1A–C).
PSMα1 was more active than PSMα3 and Hld. The release of
both LDH and tryptase was significantly higher with PSMα1
than with PSMα3 and Hld (p < 0.05), with the maximal release
of tryptase and LDH in the presence of 200 µg/mL toxin (i.e.,
88, 76 and 66 µM for PSMα1, PSMα3, and Hld respectively),
achieving levels as high as 106.58 ± 17.29 and 89.99 ± 4.89%
of the positive control with PSMα1, 27.69 ± 18.09 and 39.41 ±
6.74% with PSMα3, and 51.00 ± 8.25 and 28.66 ± 4.08% with
Hld. The lowest toxin concentration inducing tryptase and LDH
release was 0.5 µg/mL for PSMα1 (i.e., 0.22 µM) and Hld (i.e.,
0.16 µM) and 5 µg/mL for PSMα3 (i.e., 1.9 µM). Using PSMα1,
PSMα3, and Hld, tryptase levels correlated with the LDH levels,
suggesting that tryptase release was directly linked to mast cell
lysis (Supplementary Figure 3).
In contrast to PSMs and Hld, PVL and Hla did not induce
tryptase or LDH release by HMC-1 cells, even when applied at
high concentrations (5 µg/mL, i.e., 0.15 µM) (Figure 1D). This
negative data were not associated with the absence of activity
in PVL and Hla preparations because they caused membrane
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FIGURE 1 | (A) Effect of S. aureus PSMα1, (B) PSMα3, (C) Hld, and (D) PVL and Hla on human mast cells. HMC-1 cells were incubated with increasing doses of
PSMα1, PSMα3, Hld (from 0.1 µg/mL, i.e., around 4 × 10−8 M to 200 µg/mL, i.e., around 8 × 10−5 M), PVL (from 0.05 µg/mL, i.e., 1.5 × 10−9 M to 5 µg/mL, i.e.,
1.5 × 10−7 M), or Hla (3 × 10−7 M) for 3 h at 37◦C. Tryptase and LDH release were measured in cell supernatants by Immunocap (Phadia®) and Architect (Abbot®),
respectively. The percentage of mast cell degranulation and mast cell lysis was calculated as Test−TnegTpos−Tneg × 100. The negative control and positive control were
performed with cell buffer and lysis buffer, respectively. The values represent the mean + SD of at least three independent experiments. To evaluate the
dose-dependency on LDH and tryptase release, we performed Kruskal-Wallis tests for PSMα1, PSMα3, and Hld (p < 0.001 for the three toxins). To evaluate the
lowest concentration inducing LDH or tryptase release that was significantly different from Tneg, t-tests of mean to 0 (Tneg) were performed for each toxin
concentration. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
disruption of humans PMNs and rabbit erythrocytes, respectively
(Supplementary Figures 1, 2).
Effect Of S. aureus Supernatants on
HMC-1 Cells
We quantified Hla, PVL, PSMα1, PSMα3, and Hld in
supernatants of SF8300 and its isogenic mutants to confirm
their toxin production profiles. As expected, the concentrations
of Hla and PVL in SF8300WT, SF8300Hld(3G > T), and
SF83001psmα1–4 supernatants were similar (Hla: 0.4, 0.4, 0.4
µg/mL; PVL: 18, 25, 26 µg/mL), whereas only a small amount of
Hla and PVL was detected in SF83001agrA supernatant (0.001
and 0.2 µg/mL, respectively). SF8300WT produced PSMα1 (4.07
± 0.41 µg/mL), PSMα3 (3.00 ± 0.10 µg/mL), and Hld (50.06
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± 6.45 µg/mL), whereas SF8300Hld(3G > T) produced only
PSMα1 (6.30 ± 0.64 µg/mL) and PSMα3 (1.62 ± 0.05 µg/mL),
SF83001psmα1–4 produced only Hld (44.86± 5.70µg/mL), and
SF83001agrA produced none of the mediators (Figure 2).
When we examined the effect of the supernatant from
the S. aureus SF3800 strain on HMC-1 cells, we observed
that LDH and tryptase concentratons were consistent with
the effect of synthetic peptides PSMα1, PSMα3, and Hld.
FIGURE 2 | Effect of SF8300WT, SF83001psmα1-3, SF8300Hld(3G >T), and SF83001agrA on human mast cells. HMC-1 cells were incubated with 20, 10,
or 5% v/v S. aureus supernatants for 3 h at 37◦C. (A) LDH and (B) tryptase release was measured in cell supernatants by Architect (Abbot®) and Immunocap
(Phadia®), respectively. The percentage of mast cell lysis and mast cell degranulation was calculated as Test−TnegTpos−Tneg × 100. The negative control and positive control
were performed with medium and lysis buffer, respectively. The values represent the mean + SD of at least three independent experiments. (C) Hld, PSMα1, and
PSMα3 concentrations in in each supernatant. To compare LDH and tryptase release by HMC-1 cells challenged with SF8300WT, SF83001psmα1-3,
SF8300Hld(3G > T), or SF83001agrA supernatants, we performed t-test with Bonferroni correction followed by ANOVA. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. N.S.,
not significant; N.D., not detected (toxin concentrations were less than the detection limit of 0.1 µg/mL).
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LDH and tryptase release by HMC-1 cells was concentration-
dependent (from 20 to 5% v/v; ANOVA, p < 0.01) and varied
between SF3800WT and its isogenic mutants (Figure 2).
The staphylococcal supernatant-induced levels of LDH and
tryptase release (using 20 to 5% v/v) in descending order
were from SF8300WT, SF83001psmα1–4, SF8300Hld(3G
> T), and SF83001agrA. Taken together, these results
indicate that LDH and tryptase release by HMC-1 cells
challenged with S. aureus supernatants was mainly associated
with Hld production and secondary to PSMα1 and PSMα3
production.
PSMα and Hld Quantification in Clinical
Specimens
As only PSMα1, PSMα3, and Hld induced tryptase and LDH
release by HMC-1 cells, we explored their production during
human skin infection (Table 2). Hld was detected in 15 of the
23 pus samples at concentrations ranging from 0.1 to 19.6
µg/mL (median 0.85 µg/mL). PSMα1 was detected in only four
of the pus samples at concentrations ranging from 0.1 to 3.9
µg/mL (median 0.31 µg/mL). Higher concentrations of Hld and
PSMα1 were detected in the same pus samples. Twelve of the
15 (80%) Hld-positive specimens reached toxic concentrations
for HMC-1 cells (i.e., 0.5 µg/mL), but only one pus sample
contained a toxic concentration of PSMα1 for HMC-1 cells.
Finally, PSMα3 was detected in none of the tested clinical
specimens.
In vitro PSMα and Hld Production by
s. aureus Strains
Forty-six S. aureus clinical isolates from SSTIs were studied for
PSMα1, PSMα3, and Hld production, including 23 from the
clinical specimens analyzed for in vivo PSM and Hld production.
The other 23 isolates were from the French staphylococci NRC
collection with no pus available. Strains belonged to different
agr groups and clonal complexes (Table 1): 45.6% (21/46) S.
aureus strains in agr group 1, 19.6% (9/46) in agr group 2,
and 34.8% (16/46) in agr group 3. A majority (39/46) of
strains were methicillin-susceptible S. aureus (MSSA), and five
of seven methicillin-resistant S. aureus (MRSA) strains were
luk-PV-positive. Four of the latter were community-acquired
MRSA strains belonging to the European ST 80 clone, and one
belonged to the ST8 USA300 clone. The remaining luk-PV-
positive S. aureus strains (n= 11) were MSSA.
All S. aureus strains expressed PSMα1, PSMα3, and Hld
in vitro, though at different levels (Figure 3). Nevertheless,
the mean Hld production (94.51 ± 52.02 µg/mL) was much
higher than the mean PSMα1 production (8.10 ± 7.91 µg/mL),
TABLE 2 | Hld, PSMα1, and PSMα3 concentrations in human skin abscesses and bacterial supernatants.
S. aureus isolate Pus (µg mL−1) Supernatant (µg mL−1)
Hld PSMα1 PSMα3 Hld PSMα1 PSMα3
ST 2014 0441 19.57 3.92 ND 68.84 ± 9.19 14.45 ± 4.28 0.11 ± 0.02
ST 2012 0567 3.69 ND ND 199.47 ± 67.67 33.73 ± 8.48 14.02 ± 4.96
ST 2014 1173 1.33 ND ND 77.53 ± 0.05 5.76 ± 2.11 2.89 ± 0.71
ST 2013 0774 1.31 ND ND 171.55 ± 14.38 12.16 ± 2.70 6.07 ± 2.67
ST 2015 1706 1.26 0.40 ND 88.49 ± 12.44 8.45 ± 1.72 2.94 ± 0.82
ST 2013 1442 1.13 ND ND 141.12 ± 13.58 28.52 ± 2.52 17.10 ± 7.06
ST 2012 1497 0.90 ND ND 128.72 8.91 2.07
ST 2015 1705 0.85 ND ND 52.50 ± 20.31 1.12 ± 0.89 0.07 ± 0.01
015033164401 0.82 ND ND 98.75 ± 0.69 22.04 ± 0.32 0.08 ± 0.01
ST 2014 0409 0.67 ND ND 37.79 ± 4.29 0.37 ± 0.11 0.06 ± 0.03
ST 2014 0351 0.59 0.22 ND 123.00 ± 11.62 10.42 ± 0.71 2.65 ± 0.06
ST 2015 1711 0.52 ND ND 22.15 ± 9.55 0.33 ± 0.08 0.07 ± 0.01
ST 2014 1033 0.31 0.19 ND 43.56 ± 2.02 9.02 ± 4.62 2.58 ± 1.58
ST 2012 1322 0.26 ND ND 71.81 1.61 0.42
ST 2014 0589 0.12 ND ND 143.72 ± 20.12 10.95 ± 2.94 4.13 ± 0.21
ST 2014 1539 ND ND ND 143.53 ± 25.19 20.55 ± 11.23 6.70 ± 3.86
ST 2015 1708 ND ND ND 116.15 ± 21.28 7.95 ± 2.25 4.80 ± 1.66
ST 2014 1054 ND ND ND 92.21 ± 4.28 10.19 ± 1.27 2.92 ± 0.46
ST 2014 1524 ND ND ND 53.99 ± 23.55 2.20 ± 1.53 0.44 ± 0.20
ST 2015 1710 ND ND ND 33.09 ± 2.19 4.43 ± 0.19 0.08 ± 0.01
ST 2015 1707 ND ND ND 14.70 ± 2.94 0.47 ± 0.17 0.15 ± 0.04
ST 2014 1501 ND ND ND 7.66 ± 4.91 0.14 ± 0.04 0.07 ± 0.03
ST 2015 1709 ND ND ND 4.38 ± 3.05 <0.1 0.07 ± 0.03
ND, not detected.
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which was higher than the mean PSMα3 production (3.09
± 3.79 µg/mL) (Figure 3A). The in vitro production levels
of the three toxins were not different between MRSA and
MSSA (Figures 3B–D). We did not notice any difference in
the in vitro PSMα1 and PSMα3 production levels between
luk-PV-positive (n = 16) and luk-PV-negative (n = 30)
S. aureus strains (Figures 3C,D). However, luk-PV-positive
strains produced more Hld (113.05 ± 46.42 µg/mL) than luk-
PV-negative strains (84.62± 52.86 µg/mL, p< 0.05; Figure 3B).
We also observed that S. aureus from agr group 1 produced
higher levels of Hld, PSMα1, and PSMα3 than S. aureus from
agr groups 2 and 3 (p < 0.05; Figures 3B–D). No significant
difference was found in PSMα1, PSMα3, and Hld production
between community-acquired MRSA and the other S. aureus
strains.
Regarding the 23 S. aureus strains isolated from pus, we found
higher toxin concentrations in culture supernatants than clinical
specimens (Table 2). In vitro toxin production ranged from 4.38
to 199.47 µg/mL (median 77.53 µg/mL) for Hld, from <0.1 to
33.73 µg/mL (median 8.2 µg/mL) for PSMα1, and from 0.06 to
17.1 µg/mL (median 2.07 µg/mL) for PSMα3. No correlation
was observed between in vivo and in vitro Hld quantification
(Supplementary Figure 4).
DISCUSSION
Despite progress in our knowledge of S. aureus pathophysiology,
virulence factors that favor its transmission remain enigmatic.
Hands play a significant role in the spread of S. aureus to
new hosts through contact with skin colonized or infected
by S. aureus. In the skin, dermal mast cells act in close
interaction with nerve fibers and contain substances that act
as mediators of itching (Ständer et al., 2008). In this study,
we examined whether S. aureus pore-forming toxins that are
involved in the pathophysiology of skin infection can induce
mast cell activation/lysis. We used HMC-1 cells derived from a
patient with leukemia. Even though this cell line has two major
deficiencies (cytokine-independence and lack of a functional
FcεR), it is widely used and a faithful in vitro model of normal
FIGURE 3 | Comparisons of in vitro PSMα1, PSMα3, and Hld production in 46 S. aureus SSTI strains. HPLC-MS was performed on supernatants from 22-h
cultures. We performed t-tests Bonferroni correction followed by ANOVA, and t-tests when it was possible (parametric) or Kruskal-Wallis tests followed by Wilcox tests
with Bonferroni correction (non-parametric). (A) Comparison of toxin production. (B) Comparison of in vitro Hld, (C) PSMα1, and (D) PSMα3 production according to
agr group, methicillin resistance, and luk-PV carrier. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. N.S., not significant.
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mast cells (Drexler and MacLeod, 2003). We verified that HMC-
1 cells produce tryptase, one of the best indicators of mast cell
activation (Schwartz et al., 2003; Guhl et al., 2010), and express
CD88 similar to human skin mast cells (Füreder et al., 1995;
Werfel et al., 1996) (Supplementary Figure 5).
Our results clearly demonstrate that PSMα1, PSMα3, and Hld
induce dose-dependent tryptase and LDH release by HMC-1
cells. We suspect that tryptase liberation was mainly the result
of mast cell lysis. In contrast, PVL and Hla did not induce human
HMC-1 cell degranulation or lysis. This finding was unexpected
because König et al. (1995) reported that PVL induces histamine
release by human basophilic granulocytes, immune cells that are
morphologically and functionally related to mast cells, especially
given that the HMC-1 cell line expresses C5aR, the PVL receptor
(König et al., 1995; Spaan et al., 2013). Two major hypotheses are
possible to explain this discrepancy. Either HMC-1 cells do not
express enough CD88 to make the cell sensitive to PVL and/or
there is an additional specific co-receptor necessary for PVL
to be active that is missing from HMC-1 cells. Supplementary
investigations should be performed to test these hypotheses.
We found a similar cytotoxic effect of PSMα1 and PSMα3
on HMC-1 cells as those previously reported with human
neutrophils. The lethal concentration 50% was achieved in both
mast cells and human neutrophils at 25 µg/mL PSMα1 (Löﬄer
et al., 2010). However, for PSMα3, we observed only 20%
lysis of mast cells at the concentration that results in the 80%
lysis of neutrophils (i.e., 50 µg/mL) (Löﬄer et al., 2010). We
observed the same level of Hld activity against mast cells as
Nakamura et al.; using 10 µg/mL we measured 13.30 ± 3.01%
tryptase release, whereas they reported β-hexosaminidase release
of∼10% (Nakamura et al., 2013). The only difference was that β-
hexosaminidase release by Hld seems to not be related to cell lysis
of the mouse MC/9 mast cell line, which is in contrast to what
we observed with HMC-1 cells. This may be due to the different
origins of the mast cell lines.
In order to determine whether PSMα1, PSMα3, and Hld
are expressed in vivo, 23 pus samples recovered from human
S. aureus skin abscesses were analyzed. We detected the presence
of Hld in 65% of the analyzed clinical specimens and PSMα1
in 17% of the samples, but no PSMα3. The concentration of
Hld and PSMα1 detected in pus samples was 50- and 10-fold
lower, respectively, than the concentrations produced in vitro
and did not correlate. The weakest toxin concentration in vivo
may indicate that the toxins were degraded more rapidly in pus
than in supernatants, despite similar storage procedures. Only
50% of pus samples contained sufficient Hld levels to induce
HMC-1 cell lysis, but it was 100% with the in vitro supernatants.
In vitro Hld production was 10-fold higher than mean PSMα1
production and 30-fold higher than PSMα3 production as
described previously (Berlon et al., 2015).
Two studies recently demonstrated that PSM and Hld
production by MRSA and MSSA is higher among SSTI
isolates than either infectious endocarditis or hospital-acquired
pneumonia (Berlon et al., 2015; Qi et al., 2016). These
observations suggested that the level of PSM and Hld correlates
more with the disease than the methicillin-resistant status. As
PSM and Hld production is regulated by the agr, the level of PSM
and Hld production may reflect agr activity and its requirement
for the development of skin infection in humans, as in animal
models of S. aureus skin infection (Montgomery et al., 2010;
Cheung et al., 2011). Looking at the impact of agr alleles in
our sample, strains in agr group 1 produced more Hld, PSMα1,
and PSMα3 than those from groups 2 and 3, despite CA-MRSA
belonging mainly to agr group 3 (Tristan et al., 2007).
The involvement of PSMα1–3 in SSTI pathogenesis was
demonstrated by Wang et al., who showed that S. aureus
strains producing PSMα are more virulent, notably through
the capacity of PSMα to lyse neutrophils (Wang et al., 2007).
Recently, Syed et al. highlighted the involvement of S. aureus
PSMα, including Hld, in the induction of skin inflammation
through pro-inflammatory cytokine release from keratinocytes
(Syed et al., 2015). Skin mast cells are very important immune
cells and participate in the fight against pathogens, but they
can be deleterious when over-stimulated (Abraham and St.
John, 2010; Urb and Sheppard, 2012; St. John and Abraham,
2013). This deleterious effect has been shown in mice, with Hld
participating in the development of atopic dermatitis (Nakamura
et al., 2013). Therefore, our results suggest that S. aureus
produces Hld during acute skin infection, and to a lesser
extent PSMα1, which induces mast cell degranulation and/or
lysis directly or indirectly through skin inflammation. This
human skin mast cell degranulation activates neuroreceptors
on sensory nerve fibers involved in the induction of pruritus
and explain the itchy feeling during S. aureus skin infections
(Zhu et al., 2015). We speculate that the scratching behavior
induced by S. aureus though Hld and PSM production promotes
S. aureus transmission via hand-to-skin contact in the presence
of S. aureus-infected skin lesions, thereby promoting S. aureus
epidemicity. As highlighted previously, agr is a key regulatory
system for the maintenance of S. aureus virulence, which is
considered a key factor for host-to-host transmission (Massey
et al., 2006). Moreover, Hld is encoded by RNAIII, the effector
of agr (Novick et al., 1993). We hypothesize that the Hld–agr
association contributes to the elective transmission of virulent
S. aureus strains with a functional agr system. Altogether could
participate in the epidemic success of certain S. aureus strains,
such as the pandemic CA-MRSA USA300 clone that strongly
expresses toxins with the help of the agr system, induces itchy
skin infections, and is pandemic in the USA (DeLeo et al., 2010;
Cheung et al., 2011; Suchard, 2011).
In conclusion, our results demonstrate that Hld and PSMα1
are produced by S. aureus in vivo and induce human mast cell
degranulation and lysis. As mast cell mediators are known to
be involved in the induction of pruritus, we hypothesize that
S. aureus may promote its transmission via the hands through
scratching of infected skin lesions prompted by Hld and PSM
production.
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